The US Food and Drug Administration (FDA) has approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency.
Shield Therapeutics’ Accrufer was initially approved in 2019 for adults with iron deficiency.
Iron deficiency is the most common cause of anemia and occurs if there is not enough iron in the blood. Without enough iron, the body cannot make sufficient hemoglobin, a protein inside red blood cells that carries oxygen throughout the body.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze